Patterns of vitamin D analog use for the treatment of psoriasis

Journal of Drugs in Dermatology

Volumn 12, Issue 8, 2013, Pages 906-910

  Ahn, Christine S ^a   Awadalla, Farah ^c   Huang, Karen E ^a   Yentzer, Brad ^a   Dabade, Tushar S ^a,b   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c Derm Surgery Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CALCIPOTRIOL; VITAMIN D DERIVATIVE;

ARTICLE; CAUCASIAN; CORTICOSTEROID THERAPY; DERMATOLOGIST; DISEASE SEVERITY; FEMALE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PSORIASIS; SECONDARY ANALYSIS; UNITED STATES;

ADMINISTRATION, CUTANEOUS; BETAMETHASONE; CALCITRIOL; CROSS-SECTIONAL STUDIES; DERMATOLOGIC AGENTS; FEMALE; GLUCOCORTICOIDS; HEALTH CARE SURVEYS; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PSORIASIS; TIME FACTORS; UNITED STATES; VITAMIN D;

EID: 84882412879     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009 Feb;60(2):218-24.
2. Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol. 2001;2(2):95-120.
3. Fenton C, Plosker GL. Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris. Am J Clin Dermatol. 2004;5(6):463-78.
4. Del RJ, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S50-S58.
5. Feldman SR, Matheson R, Bruce S, Grande K, Markowitz O, Kempers S, et al. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaquetype psoriasis: results of two multicenter, randomized, double-blind, vehiclecontrolled, phase III clinical trials. Am J Clin Dermatol. 2012 Aug 1;13(4):261-71.
6. Ashcroft DM, Po AL, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ. 2000 Apr 8;320(7240):963-7.
7. Murphy G, Reich K. In touch with psoriasis: topical treatments and current guidelines. J Eur Acad Dermatol Venereol. 2011 Jun;25 Suppl 4:3-8.
8. Ambulatory Health Care Data. Centers for Disease Control and Prevention. Accessed at http://www.cdc.gov/nchs/ahcd.htm. 1-25-2013. 2-27-2013.
9. Cerner Multum. Accessed at: http://www.multum.com/. 2012. 2-4-2013.
10. U.S. Food and Drug Administration. National Drug Code Directory. Accessed at: http://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm. 2-1-2013. 2-4-2013.
11. National Center for Health Statistics, public use data tape documentation. 1990 National Ambulatory medical Care Survey. Hyattsville, MD: US Department of Health and Human Services, Public Health Service, Centers for Disease Control; 1992.
12. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9.
13. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector Tlymphocytes. N Engl J Med. 2001 Jul 26;345(4):248-55.
14. Strowd LC, Yentzer BA, Fleischer AB, Jr., Feldman SR. Increasing use of more potent treatments for psoriasis. J Am Acad Dermatol. 2009 Mar;60(3):478-81.
15. Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003 Jan;48(1):48-54.
16. Hong SP, Oh Y, Jung M, Lee S, Jeon H, Cho MY, et al. Topical calcitriol restores the impairment of epidermal permeability and antimicrobial barriers induced by corticosteroids. Br J Dermatol. 2010 Jun;162(6):1251-60.